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Artemether-Lumefantrine for Uncomplicated Malaria
Eskouhie Tchaparian,1,a Nancy C. Sambol,1,a Emmanuel Arinaitwe,2 Shelley A. McCormack,1 Victor Bigira,2 Humphrey Wanzira,2 Mary Muhindo,2
Darren J. Creek,3 Nitin Sukumar,4 Daniel Blessborn,5,b Jordan W. Tappero,6 Abel Kakuru,2 Yngve Bergqvist,5 Francesca T. Aweeka,7 and Sunil Parikh4
1Department of Bioengineering and Therapeutic Sciences, University of California San Francisco; 2Infectious Diseases Research Collaboration, Kampala, Uganda; 3Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, Australia; 4Yale School of Public Health, New Haven, Connecticut; 5Dalarna University, Uppsala, Sweden; 6Centers for Global Health, Centers for Disease
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Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment
for malaria, artemether-lumefantrine, has not been adequately characterized in young children.
Methods. Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan chil-
dren, ages 6 months to 2 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine.
Results. Population pharmacokinetics for lumefantrine used a 2-compartment open model with ﬁrst-order absorption. Age had
a signiﬁcant positive correlation with bioavailability in a model that included allometric scaling. Children not receiving trimetho-
prim-sulfamethoxazole with capillary whole blood concentrations <200 ng/mL had a 3-fold higher hazard of 28-day recurrent
parasitemia, compared with those with concentrations >200 ng/mL (P = .0007). However, for children receiving trimethoprim-
sulfamethoxazole, the risk of recurrent parasitemia did not differ signiﬁcantly on the basis of this threshold. Day 3 concentrations
were a stronger predictor of 28-day recurrence than day 7 concentrations.
Conclusions. We demonstrate that age, in addition to weight, is a determinant of lumefantrine exposure, and in the absence of
trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant of recurrent parasitemia. Exposure levels in children aged 6
months to 2 years was generally lower than levels published for older children and adults. Further reﬁnement of artemether-lume-
fantrine dosing to improve exposure in infants and very young children may be warranted.
Keywords. Malaria; population pharmacokinetics; lumefantrine; artemisinin combination therapy; antimalarial; nonlinear
mixed effects modeling; pharmacodynamics; trimethoprim-sulfamethoxazole.
Despite major strides in control of malaria, an estimated 214
million cases occurred in 2015, mainly in sub-Saharan African
children [1]. Artemisinin-based combination therapies (ACTs)
are the mainstay of therapy, with artemether-lumefantrine (AL)
used as ﬁrst- or second-line therapy in >40 countries in Africa
[1]. AL combines artemether, a fast-acting, highly efﬁcacious,
short–half-life drug, with lumefantrine, a long–half-life
(approximately 4.5 days) partner drug that eliminates residual
parasites and reduces the risk of developing resistance [2].
In Asia, growing resistance to artemisinins and partner
drugs, particularly piperaquine, has been reported [3–5]. Im-
proper dosing of ACTs is an important determinant of inade-
quate efﬁcacy and contributes to the development of resistance
[6]. Among the groups at highest risk of underdosing are young
children [7–10]. For AL, a recent meta-analysis of individual
day 7 lumefantrine concentrations suggested that exposure
was lowest in children <3 years of age, particularly those who
were underweight (low weight for age) [8]. In addition, a day
7 lumefantrine concentration of <200 ng/mL was most predic-
tive of the risk of recurrent malaria [8].
The overwhelming majority of studies of young children have
involved drug sampling only on day 7. A very small number of
children in this age range have undergone population pharma-
cokinetic (PK) analysis, and even fewer underwent PK combined
with pharmacodynamic (PD) analysis [8,11–13].The purpose of
this study was to characterize the population PKs and PDs of lu-
mefantrine in a cohort of Ugandan children 6 months to 2 years
of age. This investigation included the evaluation of clinical
and demographic covariate effects on lumefantrine exposure,
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including the use of trimethoprim-sulfamethoxazole (TMP-
SMZ) prophylaxis for those infected with or exposed to
human immunodeﬁciency virus (HIV) [14,15], as well as the re-
lationship between concentration and clinical outcome.
METHODS
Study Area and Patient Enrollment
The study was conducted in a high-transmission area of Ugan-
da [16]. PK/PD study participants were part of a larger random-
ized clinical trial comparing the antimalarial efﬁcacy of AL
versus that of dihydroartemisinin-piperaquine in young
children (Supplementary Materials) [17–19]. Daily TMP-SMZ
prophylaxis was given to all HIV-infected participants. HIV-
exposed participants received TMP-SMZ until completion of
breast-feeding, and if they remained HIV-uninfected, they
were randomly assigned to continue TMP-SMZ therapy until
2 years of age or to discontinue prophylaxis [18]. HIV-infected
participants were provided triple-drug antiretroviral therapy
(ART) with nevirapine, lamivudine, and either stavudine or zi-
dovudine, according to national guidelines. The PK/PD subtudy
population consisted of children randomly assigned to receive
AL for each episode of malaria occurring during longitudinal
follow-up. Supplementary Figure 1 depicts the breakdown of
HIV status, ART use, and TMP-SMZ use among substudy
participants.
Diagnosis and Treatment of Malaria
Uncomplicated P. falciparum malaria was diagnosed in patients
with both a positive thick blood smear (regardless of parasite
density) and either a documented fever (tympanic temperature,
>38.0°C) or a 24-hour history of fever. Clinical evaluation was
made on days 0 (the day of diagnosis), 1, 2, 3, 7, 14, 21, and 28.
Primary outcome was the 28-day risk of recurrent parasitemia.
Sixty-three-day risk of recurrent malaria (parasitemia with a
documented fever or a 24-hour history of fever) and polymerase
chain reaction genotyping to distinguish new from recrudescent
infections were assessed as secondary outcomes [20]. Children
were eligible for repeat PK sampling with each malaria episode
during follow-up.
Treatment Regimen
AL (Coartem, Novartis Pharmaceuticals) was administered as a
ﬁxed dose according to body weight at the time of diagnosis. All
children received the same dose—20 mg of artemether and 120
mg of lumefantrine (1 tablet) twice daily over 3 days—because
all body weights were <14 kg. All morning clinic doses were ad-
ministered in the clinic as crushed tablets dispersed in approx-
imately 5 mL of water, followed by administration of 150 mL of
reconstituted cow’s milk containing approximately 5 g of fat or
breast-feeding, to ensure optimal and consistent absorption of
lumefantrine [21]. Evening doses were provided to parents with
milk powder. Full doses were readministered if vomiting
occurred within 30 minutes.
Sample Collection and Analysis
A total of 100 µL of capillary whole-blood was collected into
heparinized microtubes on day 0 (before the ﬁrst dose), day 2
(before the ﬁfth dose), day 3 (12 hours after the last dose),
day 7 (108 hours after the last dose), and day 14 (276 hours
after the last dose); Supplementary Figure 1. Blood was expelled
onto Whatman 31ET Chr Chromatography paper pretreated
with 0.75 M tartaric acid per validated methods [22] and later
shipped and analyzed in the laboratory of one of the authors
(Y. B.) with a lower limit of quantiﬁcation (LLOQ) of 132 ng/
mL and a limit of detection (LOD) of 52 ng/mL [22].
Pharmacokinetic Analysis
Population PK analysis with nonlinear mixed-effects modeling
was conducted using Monolix software, version 4.3 (Lixoft,
Orsay, France; Supplement) [23]. The structural model was de-
ﬁned as a 2-compartment open model with ﬁrst-order absorp-
tion and linear elimination. Owing to limited data in the
absorption phase, the rate constant of absorption (ka) was
ﬁxed to the previously reported value of 0.45 h−1 [24]. Disposi-
tion parameters of the model were capillary whole-blood clear-
ance/bioavailability (CL/F ), central volume of distribution/F
(V1/F), intercompartmental clearance/F (Q/F), and peripheral
volume of distribution/F (V2/F ). A 1-compartment model
was also tested. Data did not support testing of more complex
structural models (eg, a 3-compartment model). Allometric
scaling was included unconditionally in all models, including
the basic model absent of other covariates, with respect to the
2 clearance parameters by multiplying each parameter by
[weight/reference weight]0.75 and, for the 2 volume terms, by
multiplying each parameter by [weight/reference weight]. The
reference weight was taken to be the median, 9.0 kg, except
for the ﬁnal model, in which it was taken to be that of a
1-year-old child, 8.43 kg. Interindividual variability and inter-
occasion variability, modeled as log-normal distributions,
were estimated for each parameter except Q/F and V2/F, for
which interoccasion variability was ﬁxed at 50%, and ka,
which was ﬁxed at 0. The covariates sex, weight, age, weight-
for-age z scores (calculated using World Health Organization
standards [25]), hemoglobin level, parasite density (log trans-
formed), HIV status, ART use, breast-fed status, and TMP-
SMZ prophylaxis (Table 1) were evaluated for their inﬂuence
on PK (Supplement).
Association Analysis Between Day 7 Lumefantrine Concentration and
Recurrent Malaria
Only P. falciparum infection episodes were included in the PD
analysis. The risk of recurrent malaria was analyzed using Cox
proportional hazard regression with a robust sandwich estima-
tor, which accounts for repeated episodes and censoring of pa-
tients with incomplete follow-up. Covariates evaluated were age
group, parasite density (log transformed), residence (urban vs
rural), hemoglobin level, TMP-SMZ use, HIV status, day 3 or
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day 7 capillary whole-blood lumefantrine concentration, and
being underweight, based on a weight-for-age z score with a
−2 cutoff [25]. For the PD analysis, PK values below the LOD
were treated as 0, and those below the LLOQ were retained as
measured. Statistical signiﬁcance was deﬁned as a 2-sided P
value of <.05. Stata, version SE12.1 (StataCorp, College Station,
TX), and SAS, version 9.4 (SAS Institute, Cary, NC), were used.
RESULTS
A total of 105 children participated in PK sampling and expe-
rienced 249 episodes of malaria subjected to PK sampling over
the 6-month period. In 99.5% of treatments included in the
analysis, the full course of 6 doses was taken.
Population Pharmacokinetic Data
For the population PK analysis, 207 episodes in 101 children
were included and contributed 806 evaluable capillary whole-
blood concentration-time data (Figure 1; Supplementary Mate-
rials). A summary of demographic and clinical characteristics of
the participants is in Table 1. The median total body weight–
adjusted lumefantrine dose was 84.7 mg/kg (range, 65.4–118.0
mg/kg) for children aged ≤12 months, 80.0 mg/kg (range,
55.4–116.1 mg/kg) for children aged 12–18 months, and 72
mg/kg (range, 54.1–90.0 mg/kg) for children aged ≥18 months.
Underweight children received a higher median milligrams per
kilogram dose than children with a z score greater than or equal
to −2 (90.0 vs 77.4 mg/kg; P < .001).
Population Pharmacokinetic Model
The ﬁnal population PK model for capillary whole-blood lume-
fantrine concentrations was a 2-compartment model with
ﬁrst-order absorption. A 1-compartment model resulted in a
signiﬁcantly worse ﬁt. Age was identiﬁed as having a signiﬁcant
inﬂuence on F despite modeling clearance and volume of distri-
bution parameters with allometric scaling. The model for F is as
follows: ~Fi = [1*Agei/12]
0.596, in which ~Fi is the typical value of
bioavailability, Agei is the age of the i
th child, 12 is the reference
age of 12 months, and 0.596 is an estimated value. The ﬁnal
population parameter estimates are provided in Table 2. The
prediction of CL/F in a typical 12-month-old child is 2.19 L/h,
with 8% (CV) interindividual variability and 9% interoccasion
variability. The point estimate of residual error (standard devia-
tion) was 37.8% (proportional) and 19.2 ng/mL (additive). Fig-
ure 2 shows the prediction intervals of capillary whole-blood
lumefantrine concentration. Half of all children are predicted
to reach the LOD (52 ng/mL) in approximately 10 days. Figure 3
demonstrates the goodness of ﬁt of the ﬁnal model.
Table 1. Characteristics of Patients in the Population Pharmacokinetics
(PK) and Outcomes Data Sets
Parameter
Population PK Data
Set (n = 101)
PK Outcomes Data
Set (n = 100)
Malaria episodes, no.
Overall 207 222
Per child
1 101 100
2 56 62
3 34 35
4 12 19
5 4 6
Malaria episodes per child, no.,
median (range)
1.9 (1–5) 2.0 (1–5)
Episodes in male children, % 47.3 47.8
Weight, kg, median (range) 9.1 (6.1–13.0) 9.0 (6.1–13.3)
Total lumefantrine dose per
treatment course, mg/kg,
median (range)
81.1 (55.4–118.0) 80.0 (54.1–118.0)
Age, mo, median (range) 14.4 (6.6–22.2) 14.9 (6.6–24.2)
6 to <12 50 49
12–18 120 126
>18 to 24 37 47
Hemoglobin level at diagnosis,
g/dL, median (range)
10.0 (5.6–15.9) 10.0 (5.6–15.9)
Parasite density, parasites,
geometric mean no./µL (95%
CI)
15 568 (128–
159 393)
17 603 (13 762–
22 516)
HIV-infected children
Overall 9 8
Malaria episodes, no. 16 18
Episodes involving urban-resident
children, no. (%)
Not included 16 (7.2)
Episodes involving breast-feeding
children, no. (%)
95 101 (46)
Children receiving TMP-SMZ
prophylaxis
Overall, no. 47 43
Malaria episodes, no. 80 85
Episodes in underweight children,
no. (%)
26 (12.6)a 29 (13.1)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IQR,
interquartile range; TMP-SMZ, trimethoprim-sulfamethoxazole.
a Median z score in the population PK data set was −0.74 (IQR, −3.63–2.08).
Figure 1. Capillary whole-blood lumefantrine concentration-time profiles in
Ugandan children ages 6 months to 2 years after 3 days of twice-daily dosing of
120 mg in combination with 20 mg of artemether. Concentrations below the LOD
are presented as gray stars at the LOD value (52 ng/mL) on days 14 and 7 (most
are stacked on top of one another).
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Supplementary Figure 2A–C shows individual data and predic-
tions for the ﬁrst 18 individuals and demonstrate that retaining
data less than the LOD (although the exact value is unknown)
informed the predictions.
Clinical Outcome Following Artemether-Lumefantrine Therapy
Of the 249 episodes enrolled in the PK/PD study, 222 episodes
in 100 children were analyzed for 28-day outcome (Table 1). For
the 137 episodes in which TMP-SMZ was not received, 59.1%
(81), 19.7% (27), and 21.2% (29) were classiﬁed as adequate
clinical and parasitological response (ACPR), late clinical failure
(LCF), and late parasitological failure (LPF), respectively.
Among the 85 in which TMP-SMZ was received, 65.9% (56)
were classiﬁed as ACPR, 5.9% (5) as LPF, and 28.2% (24) as
LCF. At 63 days, 65.8% of episodes (146 of 222) were followed
by an episode of recurrent malaria (LCF), with 95.9% (139 of
145) classiﬁed as new infection by multilocus genotyping (gen-
otyping was unsuccessful in 1 sample).
Day 3 or 7 Lumefantrine Concentration and Clinical Outcomes
The median concentration of lumefantrine on day 3 (n = 187
samples) was 2777 ng/mL (interquartile range [IQR], 1672–
4760 ng/mL) and on day 7 (n = 216 samples) was 216 ng/mL
(IQR, 136–345 ng/mL). Concentrations of lumefantrine on
day 7 differed signiﬁcantly in patients receiving TMP-SMZ
(median, 243 ng/mL; IQR, 158–424 ng/mL; n = 85) versus
those not receiving TMP-SMZ (median, 206 ng/mL; IQR,
129–302 ng/mL; n = 131; P = .018). While the total milligrams
per kilogram dose was slightly higher in children receiving
TMP-SMZ as compared to those not receiving TMP-SMZ
(mean, 82.4 vs 78.3 mg/kg, respectively; P = .01), the total mil-
ligrams per kilogram dose did not explain the difference in lu-
mefantrine levels between these groups. Concentrations on day
3 did not differ statistically, based on TMP-SMZ status.
The hazard of recurrent malaria (recurrent parasitemia or par-
asitemia plus fever) by 28 days is described in Table 3. Our re-
ceiver operating characteristic (ROC) curve analysis suggested
that a day 7 capillary whole-blood lumefantrine concentration
of approximately 200 ng/mL was the optimal cutoff for predict-
ing the risk of 28-day recurrence, particularly for children not re-
ceiving TMP-SMZ (area under the ROC curve, 0.684). In our
multivariate analysis, signiﬁcant interaction was present between
TMP-SMZ use and lumefantrine concentration (P = .0005). For
children not receiving TMP-SMZ prophylaxis, a day 7 concen-
tration of lumefantrine of <200 ng/mL conferred a 3-fold higher
hazard of recurrent malaria as compared to concentrations of
≥200 ng/mL (hazard ratio, 2.97; 95% conﬁdence interval, 1.59–
5.55; P = .0007). For children receiving TMP-SMZ prophylaxis,
the 28-day risk of malaria did not signiﬁcantly vary on the
basis of this threshold (hazard ratio, 0.50; 95% conﬁdence inter-
val, .22–1.13; P = .10). The 28-day cumulative risk of recurrent
parasitemia, stratiﬁed by lumefantrine concentration threshold
of 200 ng/mL and TMP-SMZ use, is shown in Figure 4. The
Table 2. Pharmacokinetics (PK) Parameter Estimates of Lumefantrine in
Capillary Blood for Ugandan Children 6 Months to 2 Years of Age
Variable
Point
Estimate RSE, %
IIV, %
(RSE, %) IOV (%)
Population PK parameter
CL/F (L/h)a 2.19 8 8 (174) 9.3 (105)
V1/F (L/8.43 kg) 83.2 7 15.2 (46) 8.6 (133)
Q/F (L/h)a 0.23 35 50c 50c
V2/F (L/8.43 kg) 441 74 50c 50c
ka (h−1) 0.45c . . . . . . . . .
F 1c . . . 34.9 (23) 59.4 (8)
Age effectb 0.596 38 . . . . . .
Residual variability
Proportional (%) 37.8 5 . . . . . .
Additive (ng/mL) 19.2 18 . . . . . .
Secondary parameter
Point
Estimate IQR
95%
Prediction Interval
AUC0-∞ (μg/mL•h)
d 347.8 243.6–
510.9
94.7–940.9
Day 7 concentration (ng/mL)e 202.4 143.1–
321.6
55.0–589.5
Abbreviations: AUC0-∞, area under the curve from 0 to ∞; CL, capillary whole-blood
clearance; F, relative bioavailability; RSE, relative standard error; IIV, interindividual
variability; IOV, interoccasion variability; IQR, interquartile range; Q, intercompartmental
clearance; V1, central volume of distribution; V2, peripheral volume of distribution.
a Model: Pk•[WT/8.43]
0.75, in whichWT is total body weight, and 8.43 is the typical weight for
a 12-month-old child.
b Covariate model: F•[age/12]θx.
c Fixed.
d Median of values calculated from individual estimates (modes) of CL and F.
e Median of predicted values (modes) for individuals in population analysis with day 7
measurement (n = 99).
Figure 2. Distribution of the predicted lumefantrine capillary whole-blood lume-
fantrine concentration versus time (shaded area) for the final model superimposed
on the data (points). The median is given by the center line, and the prediction in-
tervals are indicated by the depth of shading, as shown on the scale to the right.
With inclusion of the informatively censored data below the LOD, predictions are
appropriately lower than the data at 14 days.
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Figure 3. Goodness of fit plots for the final model, illustrating individual weighted residuals IWRES, based on the conditional (cond.) mode versus time (top left) or individual
predictions (bottom left) and the normalized prediction distribution error (NPDE) plots versus time (top right) or population prediction (bottom right). Data are represented by
points (red for predicted concentrations whose actual values are below the LOD and blue for all other concentrations). Graphs patterns (absence of systematic relationships
between x and y variables) suggest reasonable specification of the structural and error models.
Table 3. Cox Proportional Hazards Regression on Recurrent Malaria by Day 28, Unadjusted and Adjusted for Covariates
Covariate Unadjusted HR (95% CI) P Value Adjusted HR (95% CI) P Value
Day 7 lumefantrine concentration <200 ng/mL
Yes 1.62 (1.05–2.64) .03 1.21 (.71–2.07) .48
No 1.00
TMP-SMZ use
Yes 0.78 (.49–1.24) .29 0.75 (.43–1.29) .30
No 1.00
TMP-SMZ*day 7 interaction .001 .0005
Without TMP-SMZ use
Day 7 concentration <200 ng/mL 2.95 (1.61–5.43) .0005 2.97 (1.59–5.55) .0007
Day 7 concentration ≥200 ng/mL 1.00 1.00
With TMP-SMZ use
Day 7 concentration <200 ng/mL 0.51 (.22–1.18) .12 0.50 (.22–1.13) .10
Day 7 concentration ≥200 ng/mL 1.00 1.00
Age group, mo .19 .29
≥18 1.58 (.72–3.48) .26 1.53 (.64–3.63) .34
12–18 1.91 (.94–3.91) .08 1.87 (.83–4.22) .13
6–12 1.00 1.00
Residence
Rural 1.53 (.52–4.44) .44 1.21 (.43–3.43) .71
Urban 1.00 1.00
Hemoglobin level (g/dL)a 0.94 (.83–1.06) .32 0.93 (.83–1.05) .25
Parasite density (parasites/µL)a 1.02 (.92–1.12) .72 1.04 (.95–1.14) .35
Underweight (dichotomized)b
Yes 1.11 (.53–2.30) .79 1.04 (.47–2.31) .93
No 1.00 1.00
Abbreviations: CI, confidence interval; HR, hazard ratio; TMP-SMZ, trimethoprim-sulfamethoxazole.
a Values on the day of diagnosis; log-transformed parasite densities were used in the analysis.
b Weight-for-age z score less than −2 or greater than or equal to −2.
Lumefantrine PK/PD in Young Children • JID 2016:214 (15 October) • 1247
63-day cumulative risk of recurrent malaria (LCF only; second-
ary outcome) is shown in Supplementary Figure 2.
We also examined the association of day 3 lumefantrine con-
centration with 28-day outcomes in 182 children who had both
day 3 and day 7 concentrations available. In our multivariate
analysis, for children not receiving TMP-SMZ, each 1-unit in-
crease in natural log–transformed day 3 lumefantrine concen-
tration was associated with a 49% reduced hazard of 28-day
recurrent malaria (P = .002). In comparison, each 1-unit in-
crease in the natural log–transformed day 7 lumefantrine con-
centration was associated with a 20% reduced hazard of 28-day
recurrent malaria (P = .002).
DISCUSSION
Dosing guidelines for AL, the most widely used ACT, are based
on ranges of body weights, with the ratio of artemether to lume-
fantrine held ﬁxed at 1:6, although the PK/PD of this regimen
has not been evaluated thoroughly in the most vulnerable pop-
ulations [17]. We report the single largest population PK/PD
data set of lumefantrine in infants and very young children
to-date. A 2-compartment model with ﬁrst-order absorption
best described our PK data, consistent with previous reports
[26–29]. The most notable ﬁnding of our PK evaluation was
that, within the age range studied, older children had a signiﬁ-
cantly larger bioavailability than younger children, after ac-
counting for allometric scaling of clearances and volumes of
distribution. Our model predicts a point estimate of relative bio-
availability of 0.7 for a 6-month-old child as compared to 1.5 in a
2-year-old child, with a value of 1 for the reference 1-year-old
population. We identiﬁed a previous report of age-dependent
lumefantrine bioavailability in children aged 3 months to 12
years [30]. In this study, in the presence of concomitant food in-
take, a doubling of age was associated with a 22% increase in lu-
mefantrine bioavailability.
Based on the pathways of elimination and transport of lume-
fantrine, a decrease in bioavailability, rather than an increase,
would be expected with maturation. Lumefantrine is eliminated
primarily via metabolism by cytochrome p450 3A4 (CYP3A4)
and is also a substrate of P-glycoprotein [31, 32]. Both are ex-
pressed in the gut wall, mature over the ﬁrst years of life, and
act in concert to limit oral bioavailability. Alternative factors
may explain our observed age-dependent increase in bioavail-
ability. One explanation may relate to immature biliary function
and reduced bile salt formation (approximately 50% of adults)
[33]. Ionization and the partitioning of lumefantrine, a highly
lipophilic drug, would be expected to exhibit a slower dissolu-
tion rate and lower permeability in the diminished intra-
duodenal bile salt environment [21, 34]. Other age-related
changes include alterations in protein binding and changes in
the gastrointestinal tract, such as maturation of intestinal muco-
sa, gastric emptying, and intestinal transit [35–37].Being able to
understand the cause of lower average concentrations in the
youngest of children is critical. For instance, no dose adjustment
may be required if changes are related to protein binding, while
adjustment may be warranted if differences are due to the
amount absorbed.
A direct comparison of our PK results to those of previous
studies is limited by differences in sampling methods (whole-
blood and use of ﬁlter paper vs plasma), matrices (capillary vs
venous) and assay methods (liquid chromatography tandem
mass spectrometry vs high-performance liquid chromatogra-
phy). In a study of children similar in weight (5–14.9 kg) to
those in our study, the average area-under-the-curve from 0
to inﬁnity (AUC0-∞) was 441–577 µg/mL•h, and the average
peak concentration (Cmax) was 5.2–6.1 µg/mL, both of which
are generally higher than our ﬁndings, although this prior
study used venous plasma, which may contain higher concen-
trations than recovered from capillary whole-blood [8, 11]. In
studies of adult patients with malaria, the AUC in venous plas-
ma has ranged from 252 to 758 µg/mL•h [12, 21, 27, 38], and in
studies of older African children (up to 13 years old) treated
under supervision and in whom lumefantrine was measured
for up to at least 14 days, the average AUC0-∞ in venous plasma
ranged from 460 to 704 µg/mL•h, compared with 345 µg/mL•h
in our study [11, 24, 30, 39]. The Cmax in these studies of older
children, and that by Mwesigwa et al, ranged from 5.6 to 9.4 µg/
mL, compared with approximately 3.9 µg/mL (90% prediction
interval, 1.5–9.8 µg/mL) in our study [9].
In contrast to AUC data, more information is available to
compare day 7 lumefantrine concentrations across different
age groups. Our data reveal that children <2 years of age have
Figure 4. Cumulative risk of recurrent parasitemia by day 28 following treatment
with artemether-lumefantrine, stratified by trimethoprim-sulfamethoxazole (TMP-
SMZ) status and lumefantrine concentration of 200 ng/mL. Cox proportional hazards
risk was adjusted for repeated measures, age, residence, underweight status, par-
asite density, and hemoglobin level on the day of diagnosis and was stratified by
TMP-SMZ status and capillary whole-blood lumefantrine threshold of 200 ng/mL.
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a median day 7 capillary whole-blood concentration of 216 ng/
mL. Two previous studies using the same sampling and matrix
reported a median day 7 concentration of 304 ng/mL (IQR,
191–523 ng/mL) in children aged 6 months to 5 years [40]
and a median of 430 ng/mL (IQR 282, 634) ng/mL in children
aged 6 months to 15 years [41]. A recent WWARN meta-anal-
ysis, which included the above studies, suggested that children
aged <3 years had the lowest day 7 exposure to lumefantrine,
particularly those with a low weight-for-age z score [8].
Our study also revealed a potential PK interaction between
TMP-SMZ and AL use, an interesting ﬁnding as TMP-SMZ
use is recommended by the World Health Organization in all
HIV-infected and HIV-exposed children until HIV can be de-
ﬁnitively excluded [42]. Children receiving TMP-SMZ had
higher day 7 lumefantrine concentrations than children not re-
ceiving TMP-SMZ (median, 243 ng/mL vs 206 ng/mL;
P = .018), a ﬁnding that was not explained by the slightly higher
milligrams per kilogram dose received by children taking TMP-
SMZ. To our knowledge, the only other study to assess the PK of
AL in the context of TMP-SMZ also found a higher level of lu-
mefantrine in children taking TMP-SMZ [43]. It should be
noted, however, that TMP-SMZ use was not identiﬁed as a sig-
niﬁcant covariate in our population PK analysis. While our cur-
rent understanding of the metabolism of lumefantrine [31],
TMP, and SMZ [44, 45] is unable to explain this ﬁnding, it is
likely incomplete, as evidenced by 2 recent studies. A study of
pregnant women receiving TMP-SMZ and meﬂoquine found
that SMZ concentrations were reduced by approximately 50%
in those receiving meﬂoquine [46], and a study of TMP-SMZ
and rifampin, a potent CYP-inducer, reported signiﬁcant re-
ductions in TMP-SMZ concentrations in those receiving rifam-
pin [47].
TMP-SMZ use, which itself provides protection against ma-
laria, also inﬂuenced lumefantrine PK/PD. Among those not
receiving TMP-SMZ, there was a nearly 3-fold higher risk of
28-day recurrence if the concentration of lumefantrine was
<200 ng/mL (P = .0007). For children receiving TMP-SMZ, lu-
mefantrine concentrations were not associated with the risk of
recrudescence, likely because of the independent protective ef-
fects of TMP-SMZ against malaria. In these children, there was
a trend towards an opposite interaction (a higher risk of recur-
rence with higher lumefantrine concentrations; Supplementary
Figure 3), these ﬁndings should be interpreted with caution.
One potential explanation could be an attenuation of the pro-
tective TMP-SMZ effect seen at higher lumefantrine levels, al-
though the mechanism behind such an effect remains unclear.
Assessment of TMP-SMZ levels and the potential impact of
TMP-SMZ on lumefantrine absorption in future studies may
be informative.
Finally, we evaluated the comparative predictive value of day
3 lumefantrine concentrations in those for whom both day 3
and day 7 concentrations were available. Our analysis revealed
that day 3 concentrations were stronger predictors of 28-day re-
currence than day 7 concentrations (HR, 0.51 and 0.80, respec-
tively; P=.002 for both). These ﬁndings are supported by our
earlier results, which suggest that AUC and day 3 lumefantrine
exposure are highly correlated (r2 = 0.94; P < .0001) [9]. If day 3
concentrations prove to be equivalent or improved predictors of
treatment outcomes than day 7 concentrations, it may be logis-
tically easier to sample at this earlier time point in future PK/PD
studies.
Our analysis has several limitations. Owing to its simplicity
and convenience, capillary sampling on treated ﬁlter papers
was used. While the use of dried blood spots is advantageous
in ﬁeld operations because it does not require plasma sample
preparation and freeze shipping, its usefulness is limited be-
cause of the need for extraction of samples in a bioanalytical
laboratory, as well as its decreased sensitivity and increased var-
iability [8, 22]. In addition, the correlation between capillary
whole-blood and venous plasma remains unclear. However,
while average concentrations were lower in capillary whole-
blood on ﬁlter paper than in venous plasma, a recent meta-
analysis did not ﬁnd an association of assay matrix and day 7
concentrations in a multivariable analysis [8].
An additional limitation was the lack of sufﬁcient sampling
times during the absorption phase, making it difﬁcult to detect
an absorption delay and related kinetics in our study. We were
able to overcome these limitations by ﬁxing the absorption rate
constant (ka) to a prior reported value of 0.45 h
−1. Additionally,
since a limited amount of material were available, we were not
able to determine the levels of desbutyl-lumefantrine (DBL) in
this investigation. Measurement of DBL levels may have been of
interest for its contribution to the therapeutic efﬁcacy of lume-
fantrine, and as a secondary point, DBL levels are of value for
the assessment of the rate and extent of CYP3A4 metabolism in
this age group and its implication on the oral bioavailability of
lumefantrine. Finally, the number of underweight children and
children taking ART limited our ability to detect an impact of
these variables on PK exposure.
In summary, a population PK approach has been used to
characterize the PK of lumefantrine in young children age 6
months to 2 years. Lumefantrine’s PK were best described by
a 2-compartment open model with ﬁrst-order absorption and
linear elimination. Of the covariates studied, age was identiﬁed
as the variable signiﬁcantly affecting lumefantrine bioavailabil-
ity. Exposure on day 7 in our patient population was generally
lower than those previously reported in older children and adults
despite higher actual milligrams per kilogram doses in this group,
though at least some of the difference may be due to a difference
in sampling methods. In addition, TMP-SMZ use was found to
modulate the association between lumefantrine exposure and re-
current parasitemia. Further investigation into the mechanisms
of altered AL exposure in young children, as well as optimization
of dosing in this age group, should be done to improve exposure
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and reduce the risk of recurrent malaria in this vulnerable
population.
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